Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;13(3):179-96.
doi: 10.1038/nrd4201.

Targeting tumour-supportive cellular machineries in anticancer drug development

Matthias Dobbelstein  1 , Ute Moll  2
Affiliations
Review

Targeting tumour-supportive cellular machineries in anticancer drug development

Matthias Dobbelstein et al. Nat Rev Drug Discov. 2014 Mar.

Abstract

Traditional anticancer chemotherapeutics targeting DNA replication and cell division have severe side effects, but they have proved to be highly successful in treating some cancers. Drugs targeting signalling oncoproteins that have gained tumour-driving functions through mutations or overexpression were subsequently developed to increase specificity and thus reduce side effects, but have limitations such as the development of resistance. Now, a new wave of small-molecule anticancer agents is emerging, targeting complex multicomponent cellular machineries - including chromatin modifiers, heat shock protein chaperones and the proteasome - which thus interfere with those support systems that are more essential for cancer cells than for normal cells. Here, we provide our perspective on the advantages and limitations of agents that target tumour-supportive cellular machineries (other than those involving DNA replication), comparing them with agents that target signalling intermediates.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Clin Cancer Res. 2012 Apr 1;18(7):1824-6 - PubMed
    1. Nat Rev Cancer. 2006 Jan;6(1):38-51 - PubMed
    1. Nat Med. 2011 Dec 11;18(1):74-82 - PubMed
    1. Nat Rev Cancer. 2010 Apr;10(4):293-301 - PubMed
    1. Cancer Chemother Pharmacol. 2011 Jan;67 Suppl 1:S15-24 - PubMed

Publication types

MeSH terms

LinkOut - more resources